A phase I and pharmacologic study of the matrix metalloproteinase inhibitor CP-471,358 in patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 55, Issue 2, 2005, Pages 136-142

  Planting, André ^a   Van Der Gaast, Ate ^a   Schöffski, Patrick ^b   Bartkowski, Michele ^c   Verheij, Coleta ^a   Noe, Dennis ^c   Ferrante, Karen ^c   Verweij, Jaap ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

CP 471,358; MMPI inhibitor; Phase I study

Indexed keywords

CP 471358; LIVER ENZYME; MATRIX METALLOPROTEINASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; TRAMADOL; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; BREAST CANCER; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG USE; ESOPHAGUS CANCER; FATIGUE; FEMALE; FREQUENCY ANALYSIS; HEADACHE; HUMAN; KIDNEY CANCER; LONG TERM CARE; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MESOTHELIOMA; MYALGIA; NAUSEA; OBSERVATION; OVARY CANCER; PRIORITY JOURNAL; RASH; SOFT TISSUE SARCOMA; SOLID TUMOR; STOMACH CANCER; UTERINE CERVIX CANCER; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ARTHRALGIA; FATIGUE; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; NEOPLASMS; PROTEASE INHIBITORS; SULFONAMIDES;

EID: 12144275458     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0905-z     Document Type: Article

References (21)

1. Benassi MS, Gamberi G, Magagnoli G, et al (2001) Metalloproteinase expression and prognosis in soft tissue sarcoma. Ann Oncol 12:75-80
2. Bisset D, O'Byrne KJ, von Pawel J, et al (2002) Phase III study of the matrix metalloproteinase inhibitor prinomastat in combination with gemcitabine and cisplatin in non-small cell lung cancer (abstract 1183). Proc Am Soc Clin Oncol 21:296a
3. Bonomi P (2002) Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer. Semin Oncol 29 [Suppl 4]:78-86
4. Bramhall SR, Rosemurgy A, Brown PD, Bowry C, Buckels JAC, for the Marimastat Pancreatic Cancer Study Group (2001) Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 19:3447-3455
5. Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JAC (2002) A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87:161-167
6. Brown PD, Giavazzi R (1995) Matrix metalloproteinase inhibition: A review of anti-tumor activity. Ann Oncol 6:967-974
7. Curran S, Murray G (2000) Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer 36:1621-1630
8. Erlichmann C, Adjei AA, Alberts SR, et al (2001) Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566. Ann Oncol 12:389-395
9. Fisher C, Gilberston-Beadling S, Powers E, Petzgold G, Poorman R, Mitchell M (1994) Interstitial collagenase is required for angiogenesis in vitro. Dev Biol 162:499-510
10. Folkman J (1995) Clinical applications of research on angiogenesis. N Engl J Med 333:1757-1763
11. Hidalgo M, Eckhardt GS (2001) Development of matrix metalloproteinases in cancer therapy. J Natl Cancer Inst 93:178-193
12. Hirte H, Goel R, Major P, et al (2000) A phase I dose escalation study of the matrix metalloproteinase inhibitor BAY 12-9566 administered orally in patients with advanced solid tumours. Ann Oncol 11:1579-1584
13. Hirte HW, Vergote IB, Jeffrey JR, et al (2001) An international multicentre phase III study of BAY 12-9556 versus placebo in patients with advanced ovarian cancer responsive to primary surgery/paclitaxel+platinum containing chemotherapy (abstract 843). Proc Am Soc Clin Oncol 20:211a
14. Hurwitz H, Humphrey J, Williams K, et al (2001) A phase-I trial of BMS-275291: a novel non-hydroxamate, sheddase sparing matrix metalloproteinase inhibitor with no dose limiting arthritis (abstract 387). Proc Am Soc Clin Oncol 20:89a
15. Levitt NC, Eskens FA, O'Byrne KJ, et al (2001) Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer. Clin Cancer Res 7:1912-1922
16. Moore MJ, Hamm J, Dancey J, et al (2003) Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21:3296-3302
17. Ohashi K, Nemoto T, Nakamura K, Nemori R (2000) Increased expression of matrix metalloproteinase 7 and 9 and membrane type 1-matrix metalloproteinase in esophageal squamous cell carcinomas. Cancer 88:2201-2209
18. Rudek MA, Figg WD, Dyer V, et al (2001) Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. J Clin Oncol 19:584-592
19. Sier CF, Kubben FJ, Ganesh S, Heerding MM, Griffioen G, Hanemaaijer R, van Krieken JH, Lamers CB, Verspaget HW (1996) Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer 74:413-417
20. Shepherd SA, Giaccone G, Seymour L, et al (2002) Prospective, randomized, double-blind, placebo-controlled trial of Marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada - Clinical trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 20:4434-4439
21. Sienel W, Hellers J, Morressi-Hauf A, et al (2003) Prognostic impact of matrixmetalloproteinase-9 in operable non-small cell lung cancer. Int J Cancer 103:647-651